Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Screening, diagnosis and risks associated with Hepatitis E virus infection.

Lhomme S, Legrand-Abravanel F, Kamar N, Izopet J.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):403-418. doi: 10.1080/14787210.2019.1613889. Epub 2019 May 13.

PMID:
31082277
2.

[Acute hepatitis E infection associated with Guillain-Barré syndrome in an immunocompetent patient].

Comont T, Bonnet D, Sigur N, Gerdelat A, Legrand-Abravanel F, Kamar N, Alric L.

Rev Med Interne. 2014 May;35(5):333-6. doi: 10.1016/j.revmed.2013.05.005. Epub 2013 Sep 27. French.

PMID:
24080239
3.

How should hepatitis E virus infection be defined in organ-transplant recipients?

Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J.

Am J Transplant. 2013 Jul;13(7):1935-6. doi: 10.1111/ajt.12253. Epub 2013 May 9. No abstract available.

4.

Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Vallet S, Larrat S, Laperche S, Le Guillou-Guillemette H, Legrand-Abravanel F, Bouchardeau F, Pivert A, Henquell C, Mirand A, André-Garnier E, Giordanengo V, Lagathu G, Thibault V, Scholtes C, Schvoerer E, Gaudy-Graffin C, Maylin S, Trimoulet P, Brochot E, Hantz S, Gozlan J, Roque-Afonso AM, Soussan P, Plantier JC, Charpentier C, Chevaliez S, Colson P, Mackiewicz V, Aguilera L, Rosec S, Gouriou S, Magnat N, Lunel-Fabiani F, Izopet J, Morand P, Payan C, Pawlotsky JM.

J Clin Microbiol. 2013 May;51(5):1428-33. doi: 10.1128/JCM.03032-12. Epub 2013 Feb 20.

5.

Hepatitis E.

Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR.

Lancet. 2012 Jun 30;379(9835):2477-2488. doi: 10.1016/S0140-6736(11)61849-7. Epub 2012 Apr 30. Review. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22549046
6.

Hepatitis E virus: what transplant physicians should know.

Kamar N, Legrand-Abravanel F, Izopet J, Rostaing L.

Am J Transplant. 2012 Sep;12(9):2281-7. doi: 10.1111/j.1600-6143.2012.04078.x. Epub 2012 Apr 30. Review.

7.

Hepatitis E virus and the kidney in solid-organ transplant patients.

Kamar N, Weclawiak H, Guilbeau-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, Esposito L, Cardeau-Desangles I, Guitard J, Sallusto F, Muscari F, Peron JM, Alric L, Izopet J, Rostaing L.

Transplantation. 2012 Mar 27;93(6):617-23. doi: 10.1097/TP.0b013e318245f14c.

PMID:
22298032
8.

Hepatitis E virus-specific T-cell response after transplantation.

Kamar N, Legrand-Abravanel F, Dalton HR, Izopet J.

Hepatology. 2012 May;55(5):1643; author reply 1644. doi: 10.1002/hep.25578. No abstract available.

PMID:
22234861
9.

Hepatitis E virus antibodies in blood donors, France.

Mansuy JM, Bendall R, Legrand-Abravanel F, Sauné K, Miédouge M, Ellis V, Rech H, Destruel F, Kamar N, Dalton HR, Izopet J.

Emerg Infect Dis. 2011 Dec;17(12):2309-12. doi: 10.3201/eid1712.110371.

10.

Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study.

Henquell C, Guglielmini J, Verbeeck J, Mahul A, Thibault V, Lebray P, Laperche S, Trimoulet P, Foucher J, Le Guillou-Guillemette H, Fouchard-Hubert I, Legrand-Abravanel F, Métivier S, Gaudy C, D'Alteroche L, Rosenberg AR, Podevin P, Plantier JC, Riachi G, Saoudin H, Coppere H, André E, Gournay J, Feray C, Vallet S, Nousbaum JB, Baazia Y, Roulot D, Alain S, Loustaud-Ratti V, Schvoerer E, Habersetzer F, Pérez-Serra RJ, Gourari S, Mirand A, Odent-Malaure H, Garraud O, Izopet J, Bommelaer G, Peigue-Lafeuille H, van Ranst M, Abergel A, Bailly JL.

Infect Genet Evol. 2011 Mar;11(2):496-503. doi: 10.1016/j.meegid.2010.12.015. Epub 2011 Jan 18.

PMID:
21251997
11.

Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France.

Legrand-Abravanel F, Kamar N, Sandres-Saune K, Lhomme S, Mansuy JM, Muscari F, Sallusto F, Rostaing L, Izopet J.

Emerg Infect Dis. 2011 Jan;17(1):30-7. doi: 10.3201/eid1701.100527.

12.

JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France.

Mengelle C, Kamar N, Mansuy JM, Sandres-Sauné K, Legrand-Abravanel F, Miédougé M, Rostaing L, Izopet J.

J Med Virol. 2011 Jan;83(1):132-6. doi: 10.1002/jmv.21951.

PMID:
21108350
13.

Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France.

Legrand-Abravanel F, Kamar N, Sandres-Saune K, Garrouste C, Dubois M, Mansuy JM, Muscari F, Sallusto F, Rostaing L, Izopet J.

J Infect Dis. 2010 Sep 15;202(6):835-44. doi: 10.1086/655899.

PMID:
20695798
14.

New NS5B polymerase inhibitors for hepatitis C.

Legrand-Abravanel F, Nicot F, Izopet J.

Expert Opin Investig Drugs. 2010 Aug;19(8):963-75. doi: 10.1517/13543784.2010.500285. Review.

PMID:
20629614
15.

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.

Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hézode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoël M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poynard T, Payan C, Izopet J.

J Med Virol. 2009 Dec;81(12):2029-35. doi: 10.1002/jmv.21583. Erratum in: J Med Virol. 2010 Sep;82(9):1627. Poinard, Thierry [corrected to Poynard, Thierry].

16.

Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5.

Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J.

Antivir Ther. 2009;14(5):723-30.

PMID:
19704176
17.

Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections.

Legrand-Abravanel F, Thevenet I, Mansuy JM, Saune K, Vischi F, Peron JM, Kamar N, Rostaing L, Izopet J.

Clin Vaccine Immunol. 2009 May;16(5):772-4. doi: 10.1128/CVI.00438-08. Epub 2009 Mar 25.

18.

Hepatitis E virus genotype 3 diversity, France.

Legrand-Abravanel F, Mansuy JM, Dubois M, Kamar N, Peron JM, Rostaing L, Izopet J.

Emerg Infect Dis. 2009 Jan;15(1):110-4. doi: 10.3201/eid1501.080296.

19.

Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers.

Miedouge M, Legrand-Abravanel F, Lalanne C, Saune K, Izopet J.

J Clin Virol. 2009 Feb;44(2):134-7. doi: 10.1016/j.jcv.2008.10.012. Epub 2008 Dec 24.

PMID:
19110466
20.

Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.

Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M.

J Infect Dis. 2008 Nov 15;198(10):1448-56. doi: 10.1086/592757.

PMID:
18928375
21.

Comparison of two highly automated DNA extraction systems for quantifying Epstein-Barr virus in whole blood.

Mengelle C, Legrand-Abravanel F, Mansuy JM, Barthe C, Da Silva I, Izopet J.

J Clin Virol. 2008 Nov;43(3):272-6. doi: 10.1016/j.jcv.2008.08.005. Epub 2008 Sep 25.

PMID:
18819838
22.

Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.

Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Sauné K, Pasquier C, Chatelut E, Izopet J.

J Med Virol. 2008 Sep;80(9):1523-9. doi: 10.1002/jmv.21227.

PMID:
18649340
23.

High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France.

Mansuy JM, Legrand-Abravanel F, Calot JP, Peron JM, Alric L, Agudo S, Rech H, Destruel F, Izopet J.

J Med Virol. 2008 Feb;80(2):289-93.

PMID:
18098159
24.

Full-length genome sequences of hepatitis C virus subtype 4f.

Hmaied F, Legrand-Abravanel F, Nicot F, Garrigues N, Chapuy-Regaud S, Dubois M, Njouom R, Izopet J, Pasquier C.

J Gen Virol. 2007 Nov;88(Pt 11):2985-90.

PMID:
17947520
25.

[A new system for the culture of hepatitis C virus].

Legrand-Abravanel F, Izopet J.

Med Sci (Paris). 2007 Jun-Jul;23(6-7):588-9. French. No abstract available.

26.

New natural intergenotypic (2/5) recombinant of hepatitis C virus.

Legrand-Abravanel F, Claudinon J, Nicot F, Dubois M, Chapuy-Regaud S, Sandres-Saune K, Pasquier C, Izopet J.

J Virol. 2007 Apr;81(8):4357-62. Epub 2007 Jan 31.

27.

Genetic diversity of HCV genotype 2 strains in south western France.

Thomas F, Nicot F, Sandres-Sauné K, Dubois M, Legrand-Abravanel F, Alric L, Peron JM, Pasquier C, Izopet J.

J Med Virol. 2007 Jan;79(1):26-34.

PMID:
17133555
28.

Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.

Boulestin A, Kamar N, Sandres-Sauné K, Legrand-Abravanel F, Alric L, Vinel JP, Rostaing L, Izopet J.

J Med Virol. 2006 Mar;78(3):365-71.

PMID:
16419107
29.

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.

Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Sauné K, Vinel JP, Alric L, Izopet J.

J Med Virol. 2005 Sep;77(1):66-9.

PMID:
16032749
30.

Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient.

Kamar N, Mansuy JM, Esposito L, Legrand-Abravanel F, Peron JM, Durand D, Rostaing L, Izopet J.

Am J Kidney Dis. 2005 Jan;45(1):193-6.

PMID:
15696460
31.

Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France.

Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, Vinel JP, Pasquier C, Izopet J.

J Gen Virol. 2005 Jan;86(Pt 1):107-14.

PMID:
15604436
32.

The HLA-G*0105N null allele induces cell surface expression of HLA-E molecule and promotes CD94/NKG2A-mediated recognition in JAR choriocarcinoma cell line.

Sala FG, Del Moral PM, Pizzato N, Legrand-Abravanel F, Le Bouteiller P, Lenfant F.

Immunogenetics. 2004 Dec;56(9):617-24. Epub 2004 Nov 13.

PMID:
15578261
33.

Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.

Boulestin A, Kamar N, Legrand-Abravanel F, Sandres-Saune K, Alric L, Vinel JP, Rostaing L, Izopet J.

Antimicrob Agents Chemother. 2004 Sep;48(9):3610-2.

34.

Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin.

Legrand-Abravanel F, Sandres-Sauné K, Barange K, Alric L, Moreau J, Desmorat P, Vinel JP, Izopet J.

J Infect Dis. 2004 Apr 15;189(8):1397-400. Epub 2004 Apr 1.

PMID:
15073676
35.

Soluble HLA-G1 at the materno-foetal interface--a review.

Le Bouteiller P, Legrand-Abravanel F, Solier C.

Placenta. 2003 Apr;24 Suppl A:S10-5. Review.

PMID:
12842408

Supplemental Content

Loading ...
Support Center